Abstracts of the ASH 2018 released

The American Society of Hematology (ASH) released one month ahead the abstracts and we are excited not having to wait until December during the San Diego – CA meeting. What we see on as highlights on the CART front:  

  • Bluebird bio inc reported data from the Phase I trial to treat relapsed or refractory MM showing that its bb21217 led to a response rate of 85% per International Myeloma Working Group (IMWG) criteria. bb21217 is the company’s next-generation lentiviral CAR T therapy targeting BCMA.
  • Juno Therapeutics Inc. subsidiary of Celgene Corp. reported the first data for its JCARH125, in the Phase I/II trial to treat relapsed and/or refractory MM patients. Juno said JCARH125 led to evidence of an objective response in all evaluable patients.
  • GenScript Biotech Corp. unit Nanjing Legend Biotech Co. Ltd. reported updated data from the Phase I portion of the Chinese Phase I/II trial showing that its CAR T cell therapy LCAR-B38M, led to an overall response rate (ORR) of 88% among 57 relapsed or refractory MM patients. Johnson & Johnson  holds global rights to jointly develop and commercialize LCAR-B38M under the compound name JNJ-68284528 with GenScript subsidiaries Legend Biotech USA Inc. and Legend Biotech Ireland Ltd. to treat MM.